Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

209.87
+4.302.09%
Post-market: 210.740.8656+0.41%19:58 EDT
Volume:1.83M
Turnover:382.11M
Market Cap:44.98B
PE:-23.52
High:210.26
Open:204.64
Low:202.54
Close:205.57
52wk High:224.31
52wk Low:37.88
Shares:214.34M
Float Shares:184.00M
Volume Ratio:0.73
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:17.26
PE(LYR):-35.27

Loading ...

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)

TIPRANKS
·
Aug 08

Revolution Medicines price target raised to $227 from $205 at JPMorgan

TIPRANKS
·
Aug 08

Alphabet Reports Share Stake in SpaceX, Fervo Energy and Parabilis Medicines

Reuters
·
Aug 07

Alphabet Inc. Cuts Share Stake in Revolution Medicines Inc by 10.5% to 2.9 Mln Shares - SEC Filing

THOMSON REUTERS
·
Aug 07

Bernstein Remains a Hold on Revolution Medicines (RVMD)

TIPRANKS
·
Aug 06

Revolution Medicines is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 06

Wedbush Adjusts PT on Revolution Medicines to $201 From $192.10, Maintains Outperform Rating

MT Newswires Live
·
Aug 06

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)

TIPRANKS
·
Aug 06

Revolution Medicines, Inc. : Needham Raises Target Price to $240 from $236

THOMSON REUTERS
·
Aug 06

Revolution Medicines Earns Buy as Strong RAS Portfolio Data, Robust Launch Prep, and $5.4B Capital Base Drive Price Target Increase to $291

TIPRANKS
·
Aug 06

Revolution Medicines Publishes Corporate Deck Outlining Ras(on) Inhibitor Pipeline Targeting RAS-Driven Cancers

Reuters
·
Aug 06

Revolution Medicines Q2 2026 Earnings: Daraxonrasib Advances as Spending Rises

TradingKey
·
Aug 06

Earnings Flash (RVMD) Revolution Medicines Posts Q2 Loss $3.06, vs. FactSet Est of $2.04 Loss

MT Newswires Live
·
Aug 06

Revolution Medicines, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Revolution Medicines reports Q2 EPS ($3.06), consensus ($2.06)

TIPRANKS
·
Aug 06

Revolution Medicines Q2 FY26 Net Loss Widens to $644.4 Million; R&D Expenses Rise to $394.9 Million

Reuters
·
Aug 06

Revolution Medicines Q2 EPS $(3.06) Misses $(1.98) Estimate

Benzinga Earnings
·
Aug 06

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

THOMSON REUTERS
·
Aug 06

Movement Alert|Revolution Medicines, Inc. Rises 5.23% in Regular Trading, FDA NDA Acceptance and Pre-Earnings Optimism Drive Multi-Catalyst Rally

Market Focus
·
Aug 05

Revolution Medicines Inc Expected to Post a Loss of $1.98 a Share - Earnings Preview

Reuters
·
Aug 04